scholarly journals A case of a drug reaction to sulfasalazine in a patient infected with HIV

2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Leanne Swart ◽  
Elise Schapkaitz ◽  
Anima Baiden
Keyword(s):  
Rheumatoid Arthritis ◽  
Human Immunodeficiency Virus ◽  
Drug Reaction ◽  
Supportive Treatment ◽  
Drug Reactions ◽  
Infected Female ◽  
Immunodeficiency Virus ◽  
Systemic Symptoms ◽  
Multiple Drugs ◽  
Made In

Introduction: The diagnosis of drug reaction with eosinophilia and systemic symptoms (DRESS) in human immunodeficiency virus (HIV) patients on multiple drugs with concomitant disorders presents a diagnostic challenge.Patient presentation: We describe a case of a drug reaction to sulfasalazine in a 46 year old HIV-infected female with concurrent rheumatoid arthritis which presented atypically with a marked peripheral blood plasmacytosis mimicking a lymphoproliferative neoplasm.Management and outcome: A diagnosis of DRESS was made in conjunction with the laboratory and clinical presenting findings. Sulfasalazine was immediately discontinued. The mucocutaneous rash and systemic symptoms (which included fever, lymphadenopathy and multi-organ dysfunction) resolved with supportive treatment. This included topical and systemic corticosteroids.Conclusion: In conclusion, it is important to consider drug reactions when evaluating patients infected with HIV.

scholarly journals Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Rannakoe J. Lehloenya ◽  
Sipho Dlamini ◽  
Rudzani Muloiwa ◽  
Betty Kakande ◽  
Mzudumile R. Ngwanya ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Management ◽  
Cross Reactivity ◽  
Therapeutic Trial ◽  
Drug Reactions ◽  
Dress Syndrome ◽  
Drug Eruptions ◽  
Immunodeficiency Virus ◽  
Drug Rash ◽  
Systemic Symptoms

Abstract Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

scholarly journals A Failure of Rapid Drug Desensitization

2021 ◽  
Author(s):  
Benjamin S Prewitt ◽  
Jun C Mendoza ◽  
Christopher A Coop ◽  
Samuel Weiss ◽  
James M Quinn
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Reaction ◽  
Emergency Room ◽  
Past Medical History ◽  
Drug Reactions ◽  
Immunodeficiency Virus ◽  
Desensitization Protocol ◽  
Shellfish Allergy ◽  
To Receive ◽  
Latent Syphilis

ABSTRACT We present the case of a patient who was unable to tolerate rapid drug desensitization protocol to receive a continuous penicillin (PCN) G infusion for the treatment of neurosyphilis. A 38-year-old male with past medical history for human immunodeficiency virus, migraines, PCN allergy, doxycycline allergy, shellfish allergy, and untreated latent syphilis presented to the emergency room for a posterior migraine with associated nausea, vomiting, photophobia, right-sided paresthesias, and “shaky” vision. He was diagnosed with neurosyphilis and underwent rapid drug desensitization with the goal to receive a continuous infusion of PCN G. The patient’s hospital course was complicated by intermittent drug reactions consisting of tachycardia, rash, and dyspnea, followed by periods of being able to tolerate the infusion. After being able to tolerate the recommended dose of PCN infusion, the patient was discharged home to complete the course. However, he returned almost immediately after a recurrence of symptoms at home requiring the use of intramuscular epinephrine. Ultimately, the patient was transitioned to ceftriaxone and completed the infusion course as an inpatient because of continued intermittent recurrence of drug reaction symptoms.

scholarly journals Incidence and Predictors of Sever Adverse Drug Reactions Among Patients on Antiretroviral Therapy at Debre Markos Referral Hospital, Northwest Ethiopia

2019 ◽  
Author(s):  
Getiye Dejenu Kibret ◽  
Tadesse Awoke Ayele ◽  
Adino Tesfahun
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Antiretroviral Therapy ◽  
Adverse Drug Reactions ◽  
Catchment Area ◽  
Referral Hospital ◽  
Drug Reactions ◽  
Immunodeficiency Virus ◽  
Debre Markos

Abstract Background Due to its nature of chronicity and the trend of using more drugs for patients with HIV, antiretroviral toxicity becomes a major challenge of HIV management. Evidences revealed that magnitude of experiencing at least one form of drug toxicity in different setting have been reached up to 90% among patients on antiretroviral therapy. Objective The main aim of this study was to estimate the incidence and predictors of severe adverse drug reactions among People Living with Human Immunodeficiency Virus (PLHIV) at Debre Markos Referral Hospital. Methods Retrospective follow up study with survival analysis was carried out among people living with Human Immunodeficiency virus. Mean survival time of the cohort was estimated using Kaplan-Meier method. To model the relationship between explanatory variables and the time to adverse drug reaction, Cox-proportional hazard regression model was fitted. Results Out of the total 485 participants 67 (13.81%; 95% C.I: 10.7%, 16.8%) had experienced sever adverse drug reactions (ADRs). The incidence rate of severe adverse drug reaction development was 3 per 100-person years. Patients residing out of the catchment area to the facility were 73% at higher risk to develop ADR at any time, compared to those living within the catchment area (AHR=1.73; 95% C.I: 1.04, 2.86). The risk of ADRs among patients with baseline WHO clinical stage of III and IV was 2.59 times higher at any time compared to those with WHO stages I and II (95% C.I: 1.54, 4.36). Conclusion The incidence of adverse drug reactions was relatively lower than reported in different parts of Ethiopia and other African countries. However, the overall burden in the 10 years period was still high. Health professionals working in the ART clinic need to give special attention for patients coming from outside of catchment areas, commercial sex workers and drivers and patients on advanced WHO clinical stages to prevent ADR development among these groups.

Dolutegravir as a trigger for DRESS syndrome?

2018 ◽  
Vol 29 (10) ◽  
pp. 1036-1038 ◽  
Author(s):  
Charlotte Martin ◽  
Marie-Christine Payen ◽  
Stephane De Wit
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Reaction ◽  
Second Generation ◽  
Strand Transfer ◽  
Dress Syndrome ◽  
Immunodeficiency Virus ◽  
Transfer Inhibitor ◽  
Inhibitor Drug ◽  
Systemic Symptoms ◽  
Integrase Strand Transfer Inhibitor

Dolutegravir is an increasingly-used second-generation human immunodeficiency virus integrase strand transfer inhibitor. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described in several patients treated with raltegravir but to our knowledge, there is no previous report of DRESS syndrome associated with dolutegravir.

scholarly journals Incidence and Predictors of Sever Adverse Drug Reactions Among Patients on Antiretroviral Therapy at Debre Markos Referral Hospital, Northwest Ethiopia

2019 ◽  
Author(s):  
Getiye Dejenu Kibret ◽  
Tadesse Awoke Ayele ◽  
Adino Tesfahun
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Antiretroviral Therapy ◽  
Adverse Drug Reactions ◽  
Catchment Area ◽  
Referral Hospital ◽  
Drug Reactions ◽  
Immunodeficiency Virus ◽  
Debre Markos

Abstract Background: Due to its nature of chronicity and the trend of using more drugs for patients with HIV, antiretroviral toxicity becomes a major challenge of HIV management. Evidences revealed that magnitude of experiencing at least one form of drug toxicity in different setting have been reached up to 90% among patients on antiretroviral therapy. The main aim of this study was to estimate the incidence and predictors of severe adverse drug reactions among People Living with Human Immunodeficiency Virus (PLHIV) at Debre Markos Referral Hospital. Methods: Retrospective follow up study with survival analysis was carried out among people living with Human Immunodeficiency virus. Mean survival time of the cohort was estimated using Kaplan-Meier method. To model the relationship between explanatory variables and the time to adverse drug reaction, Cox-proportional hazard regression model was fitted. Results: Out of the total 485 participants 67 (13.81%; 95% C.I: 10.7%, 16.8%) had experienced sever adverse drug reactions (ADRs). The incidence rate of severe adverse drug reaction development was 3 per 100-person years. Patients residing out of the catchment area to the facility were 73% at higher risk to develop ADR at any time, compared to those living within the catchment area (AHR=1.73; 95% C.I: 1.04, 2.86). The risk of ADRs among patients with baseline WHO clinical stage of III and IV was 2.59 times higher at any time compared to those with WHO stages I and II (95% C.I: 1.54, 4.36). Conclusion: The incidence of adverse drug reactions was relatively lower than reported in different parts of Ethiopia and other African countries. However, the overall burden in the 10 years period was still high. Health professionals working in the ART clinic need to give special attention for patients coming from outside of catchment areas, commercial sex workers and drivers and patients on advanced WHO clinical stages to prevent ADR development among these groups.

scholarly journals Incidence and Predictors of Sever Adverse Drug Reactions Among Patients on Antiretroviral Therapy at Debre Markos Referral Hospital, Northwest Ethiopia

2019 ◽  
Author(s):  
Getiye Dejenu Kibret ◽  
Tadesse Awoke Ayele ◽  
Adino Tesfahun
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Antiretroviral Therapy ◽  
Adverse Drug Reactions ◽  
Catchment Area ◽  
Referral Hospital ◽  
Drug Reactions ◽  
Immunodeficiency Virus ◽  
Debre Markos

Abstract Background Due to its nature of chronicity and the trend of using more drugs for patients with HIV, antiretroviral toxicity becomes a major challenge of HIV management. Evidences revealed that magnitude of experiencing at least one form of drug toxicity in different setting have been reached up to 90% among patients on antiretroviral therapy. Objective The main aim of this study was to estimate the incidence and predictors of severe adverse drug reactions among People Living with Human Immunodeficiency Virus (PLHIV) at Debre Markos Referral Hospital. Methods Retrospective follow up study with survival analysis was carried out among people living with Human Immunodeficiency virus. Mean survival time of the cohort was estimated using Kaplan-Meier method. To model the relationship between explanatory variables and the time to adverse drug reaction, Cox-proportional hazard regression model was fitted. Results Out of the total 485 participants 67 (13.81%; 95% C.I: 10.7%, 16.8%) had experienced sever adverse drug reactions (ADRs). The incidence rate of severe adverse drug reaction development was 3 per 100-person years. Patients residing out of the catchment area to the facility were 73% at higher risk to develop ADR at any time, compared to those living within the catchment area (AHR=1.73; 95% C.I: 1.04, 2.86). The risk of ADRs among patients with baseline WHO clinical stage of III and IV was 2.59 times higher at any time compared to those with WHO stages I and II (95% C.I: 1.54, 4.36). Conclusion The incidence of adverse drug reactions was relatively lower than reported in different parts of Ethiopia and other African countries. However, the overall burden in the 10 years period was still high. Health professionals working in the ART clinic need to give special attention for patients coming from outside of catchment areas, commercial sex workers and drivers and patients on advanced WHO clinical stages to prevent ADR development among these groups.

scholarly journals Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles

2020 ◽  
Author(s):  
Sanya J Thomas ◽  
Jacob T Kilgore ◽  
Bradford A Becken ◽  
Coleen K Cunningham ◽  
Amelia B Thompson
Keyword(s):  
Drug Reaction ◽  
Human Leukocyte Antigen ◽  
Human Leukocyte ◽  
African American Female ◽  
Dress Syndrome ◽  
Leukocyte Antigen ◽  
Antigen B ◽  
Immunodeficiency Virus ◽  
Perinatally Acquired ◽  
Systemic Symptoms

Abstract We present the first published case of raltegravir-associated drug-reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a child without characteristic human leukocyte antigen haplotypes HLA-B*57:01 or HLA-B*53:01. A 4-year-old African American female with perinatally acquired human immunodeficiency virus infection was hospitalized for DRESS after starting a raltegravir-based antiretroviral regimen.

scholarly journals S7. NEOSENSITIZATION TO MULTIPLE DRUGS FOLLOWING DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS SYNDROME (DRESS)

2018 ◽  
Vol 44 (suppl_1) ◽  
pp. S326-S326 ◽  
Author(s):  
Moon Doo Kim ◽  
Won-Myong Bahk ◽  
Young Joon Kwon ◽  
Bo-Hyun Yoon ◽  
Kwanghun Lee ◽  
...  
Keyword(s):  
Drug Reaction ◽  
Systemic Symptoms ◽  
Multiple Drugs
Sign in / Sign up

Export Citation Format

Share Document